๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Advanced Solid Tumors
Clinical trial register · China

Advanced Solid Tumors Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 2 Beijing 2 Zhengzhou 1 Hangzhou 1 Taiyuan 1
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai2 Beijing2 Zhengzhou1 Hangzhou1 Taiyuan1
All 5 locations
Target enrolment
to

Advanced Solid Tumors trials in China

6 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
NCT06895928Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 2
400
Taiyuan
2025-03-28
Not yet open
A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid Tumors
NCT06704828Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 2
20
Beijing
2024-12
Recruiting
A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors
NCT06605222Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2
201
Shanghai
2024-10-04
Recruiting
A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
NCT06474455Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2
156
Zhengzhou, Hangzhou
2024-07-02
Recruiting
A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors
NCT06417554Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2
80
Beijing
2024-05-27
Recruiting
Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors
NCT05701709Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1
395
Shanghai
2023-04-06
Rows per page Showing 1–6 of 6
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/condition/advanced-solid-tumors

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 6 of those studies listing the condition Advanced Solid Tumors that also match the filters currently applied.

How many Advanced Solid Tumors trials are recruiting in China?

5 of the 6 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 0 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Advanced Solid Tumors), 6 studies
PhaseStudiesRecruitingShare
Phase 1/23350%
Phase 22133.3%
Phase 11116.7%

Most active sponsors

Lead sponsors with the most studies (Advanced Solid Tumors)
Lead sponsorStudiesRecruiting
Shanghai Hengrui Pharmaceutical Co., Ltd.65
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.